EP300 and colorectal neoplasm: These findings support our hypothesis regarding the roles of CBP and p300 as central chromatin modifiers and suggest that epigenetic therapies specifically targeting CBP or p300 may serve as a potential option for the treatment of a subset of colorectal tumours.